Garland Jason K sold $106K of RGEN
Garland Jason K (CFO) sold 733 shares of REPLIGEN CORP (RGEN) at $145.00 ($0.11M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling activity but does not introduce new company fundamentals or guidance.
Market read
Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a major repricing on its own.
What to watch
Insider sales can be misread; without accompanying buys, guidance changes, or material company events, the trading signal is weak.
Background
The article is a primary-source SEC Form 4 insider transaction for Repligen Corp (RGEN).
Ticker impact
Repligen CFO Garland Jason K filed a Form 4 for an open-market sale of 733 shares at $145 on 2026-06-25 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited and short-lived.
The filing is a routine 10b5-1 planned sale with modest disclosed size ($106,285). The article provides no new operational, financial, or regulatory catalyst.
Market effects
No clear sector read-through from a single planned insider sale.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerREPLIGEN CORP
Subject of the Form 4 insider transaction disclosure.
- insiderGarland Jason K
CFO who sold 733 shares in an open-market transaction under a 10b5-1 plan.
